• 1
    Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005; 100: 210015.
    Direct Link:
  • 2
    Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 18818.
  • 3
    Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 51925.
  • 4
    Tatsuguchi A, Sakamoto C, Wada K, et al. Localization of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000; 46: 7829.
  • 5
    Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000; 47: 76270.
  • 6
    Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 72935.
  • 7
    Sheu BS, Yang HB, Sheu SM, Huang AH, Wu JJ. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003; 9: 524551.
  • 8
    Sheu BS, Sheu SM, Yang HB, Huang AH, Wu JJ. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2-genopositive infection. Gut 2003; 52: 92732.
  • 9
    Sheu BS, Lee SC, Yang HB, et al. Selection of a lower cut-off value for the 13C-urea breath test is mandatory to detect H. pylori infection in patients after proton pump inhibitor-based triple therapy. Dig Dis Sci 2000; 45: 13306.
  • 10
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney system: International Workshop on the Histology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 116181.
  • 11
    Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006; 12: 476672.
  • 12
    Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cylcoxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitor. J Natl Cancer Inst 2006; 98: 73647.
  • 13
    Hu PJ, Yu J, Zheng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004; 53: 195200.
  • 14
    Karin M, Cao Y, Greten FR, Li ZW. NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 30110.
  • 15
    Lin A, Karin M. NF-kappa B in cancer: a marked target. Semin Cancer Biol 2003; 13: 10714.
  • 16
    Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents: aspirin and salicylate inhibit the activity of I (kappa) B kinase-beta. Nature 1998; 396: 7780.
  • 17
    Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomized trial on Helicobacter pylori eradication. Gut 2004; 53: 12449.
  • 18
    Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001; 134: 3806.
  • 19
    Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk – where are we now? Nat Clin Pract Cardiovasc Med 2005; 2: 290300.
  • 20
    Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective an nonselective cycloxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005; 45: 74250.
  • 21
    Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risks associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1092102.